Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, today announced the pricing of
its upsized underwritten public offering of shares of its common
stock and, in lieu of common stock to certain investors that so
choose, pre-funded warrants to purchase shares of its common stock.
Disc is selling 2,595,919 shares of common stock and pre-funded
warrants to purchase 204,081 shares of common stock in the
offering. The shares of common stock are being sold at a public
offering price of $49.00 per share, and the pre-funded warrants are
being sold at a public offering price of $48.9999 per pre-funded
warrant, which represents the per share public offering price for
the common stock less the $0.0001 per share exercise price for each
such pre-funded warrant. The aggregate gross proceeds to Disc from
this offering are expected to be $137.2 million, before deducting
underwriting discounts and commissions and other estimated offering
expenses, excluding the exercise of any pre-funded warrants. In
addition, Disc has granted the underwriters a 30-day option to
purchase up to an additional 420,000 shares of its common stock at
the public offering price less underwriting discounts and
commissions. All of the securities being sold in the offering are
being offered by Disc. The offering is expected to close on June
16, 2023, subject to the satisfaction of customary closing
conditions.
Disc intends to use the net proceeds from the
offering to fund research and clinical development of its current
or additional product candidates, as well as for working capital
and other general corporate purposes.
Morgan Stanley, SVB Securities, Stifel and BMO
Capital Markets are acting as joint book-running managers for the
offering. Wedbush PacGrow is acting as lead manager for the
offering.
The securities described above are being offered
by Disc pursuant to a shelf registration statement on Form S-3 (No.
333-269272) that was declared effective by the Securities and
Exchange Commission (SEC) on January 24, 2023. This offering is
being made only by means of a prospectus and prospectus supplement
that form a part of the registration statement. A preliminary
prospectus supplement and accompanying prospectus related to the
offering has been filed, and a final prospectus supplement and
accompanying prospectus related to the offering will be filed, with
the SEC and are or will be available on the SEC’s website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering may also be
obtained, when available, by contacting: Morgan Stanley & Co.
LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, New York 10014; SVB Securities LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston,
Massachusetts 02109, telephone: 1 (800) 808-7525 ext. 6105, or by
emailing syndicate@svbsecurities.com; Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, telephone: (415)
364‐2720 or by emailing syndprospectus@stifel.com; or BMO Capital
Markets Corp., Attention: Equity Syndicate Department, 151 W 42nd
Street, 32nd Floor, New York, New York 10036, telephone: (212)
702-1101, or by emailing bmoprospectus@bmo.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that state or jurisdiction.
About Disc Medicine
Disc Medicine (NASDAQ: IRON) is a clinical-stage
biopharmaceutical company committed to discovering, developing, and
commercializing novel treatments for patients who suffer from
serious hematologic diseases. We are building a portfolio of
innovative, potentially first-in-class therapeutic candidates that
aim to address a wide spectrum of hematologic diseases by targeting
fundamental biological pathways of red blood cell biology,
specifically heme biosynthesis and iron homeostasis.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
express or implied statements related to Disc’s expectations
regarding the timing and closing of the offering, and the
anticipated use of proceeds from the offering. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “seek,” “target” and similar expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release. These risks and uncertainties include fluctuations
in Disc’s stock price, changes in market conditions, the
satisfaction of customary closing conditions related to the public
offering, and other risks identified in our SEC filings, including
our Quarterly Report on Form 10-Q for the quarter ended March 31,
2023, and in the preliminary prospectus supplement related to the
offering filed with the SEC on June 12, 2023. We caution you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. We disclaim any obligation to
publicly update or revise any such statements to reflect any change
in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com
Disc Medicine (NASDAQ:IRON)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Disc Medicine (NASDAQ:IRON)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024